Gogo reports second-quarter revenue of $222.8m

Gogo Inc reported Q2 2026 total revenue of $222.8m, down 1% YoY and 2% sequentially. Service revenue rose to $191.3m, helped by military and government service revenue of $39.9m (+40% YoY). Net loss was $2.0m. Adjusted EBITDA was $53.7m. Gogo revised FY 2026 revenue to $870m-$895m and adjusted EBITDA to $175m-$185m.

Original reporting
Published Aug 10, 2026, 10:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 10:45 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Gogo reports second-quarter revenue of $222.8m — source image
Decision brief

The 30-second read

$GOGONeutralMed
01

Why it matters

The key tradable update is the full-year 2026 guidance revision, which increases expected litigation expenses and adjusts free cash flow outlook, while also providing operational shipment metrics (Galileo terminals, Galileo online aircraft, GEO units, and 5G unit shipments) and capital allocation context (net leverage target range).

02

Market read

Traders can reprice the stock around updated FY 2026 revenue, adjusted EBITDA, and free cash flow ranges, plus the near-term cash and leverage trajectory tied to earn-out and debt payments.

03

What to watch

Investors may underweight the magnitude of the Satcom Direct earn-out and debt payments on cash, and overfocus on revenue sequencing without separating service momentum from equipment shipment cadence.

Relevance 8/10Novelty 8/10Timing: pre-market today (published 2026-08-10 10:30 UTC)

Background

Gogo is transitioning from domestic air-to-ground connectivity toward global high-speed broadband for under-penetrated business and military government aviation markets, with next-generation portfolio execution tracked via GEO/Galileo/5G shipments and FAA supplemental type certificate progress.

Company-level read

Ticker impact

$GOGONeutralMedium confidence
Context

Gogo reported Q2 2026 revenue of $222.8m, revised full-year guidance, and disclosed leverage, cash burn, and litigation expense drivers.

Expected impact

Likely choppy reaction, with downside risk if investors focus on lower equipment revenue and cash decline, offset by stronger military/government service momentum and Galileo/5G shipment progress.

Evidence & confidence

The article provides concrete Q2 results plus a full-year revenue, adjusted EBITDA, and free cash flow guidance update, along with net leverage (3.8x) and cash decline after earn-out and debt payments.

Market effects

Highlights ongoing execution risk in satcom connectivity (FAA STC delays, equipment shipment timing) versus demand strength in military/government and broadband capacity buildouts.

Limited direct regional spillover; primarily affects US-listed aerospace connectivity/satcom sentiment.

Military/government and broadband expansion themes may influence broader satcom equipment and connectivity demand expectations.

Counterpoint

The equipment revenue sequential decline may be timing-related rather than demand deterioration, and service growth plus record military/government performance could offset the guidance reset.

Key entities

  • Gogo Inc

    Reported Q2 2026 results, revised full-year 2026 revenue, adjusted EBITDA, and free cash flow guidance, and provided leverage and cash movement details.

  • Chris Moore

    CEO quoted on execution progress and military/government performance momentum.

  • Zachary Cotner

    CFO quoted on leverage priority and drivers of guidance revision, including equipment timing and litigation expense.

Related articles

$GOGOMed

Gogo Inc. (GOGO): Results of Operations and Financial Condition

Gogo Inc. (GOGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 gogo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Press Release For Immediate Release Investor Relations Contact: Media Relations Contact: Amy Greene Stacey Giglio +1 303-301-3313 +1 321-525-4607 agreene@gogoair.com sgiglio@gogoair.com GOGO ANNOUNCES SECOND QUARTER RESULTS T

$GOGOMedAI 8/10

critical communications services for ‘hurricane hunter’ aircraft

SD Government, a Gogo company, said it won a multi-year framework contract from NOAA’s Aircraft Operations Center to support the Hurricane Hunter fleet, including Lockheed Martin WP-3D aircraft “Kermit” and “Miss Piggy.” The agreement has total obligations of $7.5 million for mission communications, including L-band SATCOM, ground infrastructure, cybersecurity, and Gogo FlightDeck Freedom datalink software.

$GOGOLow

Airshare to equip fleet of Embraer Phenom 300s with Gogo Galileo connectivity

Gogo (NASDAQ: GOGO) said Airshare will equip its Embraer Phenom 300 fleet with the Gogo Galileo HDX in-flight connectivity system. Airshare tested it on a demonstration flight with 23 devices; the system transferred 16GB+ in one hour while supporting simultaneous high-bandwidth apps. Installations start this month in Wichita, Kansas, using OneWeb LEO network and targeting up to 60 Mbps.

$GILDHighAI 8/10

Gilead’s Core Business Is Accelerating, But Will Its $11 Billion Pipeline Bet Pay Off?

Gilead Sciences (GILD) reported Q2 2026 with double-digit growth in commercial portfolio sales, but posted a significant loss due to $11.2B in R&D expenses from acquisitions. HIV sales rose 12% to $5.7B, while non-HIV areas like liver disease and cancer treatments also showed growth. The company raised its 2026 sales guidance and made strategic acquisitions, but faces risks from clinical development and financial obligations.

$ABBVMedAI 8/10

AbbVie’s Humira Replacement Strategy Is Working, But Could Growth Be Too Concentrated?

AbbVie (NYSE:ABBV) reported Q2 2026 revenue of $16.99B, up 10.2%, driven by immunology and neuroscience. Skyrizi and Rinvoq revenues grew 24.4% and 24.5% respectively, offsetting Humira's 35.9% decline. However, concentration risk exists as these two products made up 47% of revenue. Oncology and aesthetics showed weaker performance, with oncology revenue down 1.5%. Adjusted EPS rose 22.9% to $3.65.